

## FOR IMMEDIATE RELEASE

Company Name: Premier Anti-Aging Co., Ltd.  
 (Securities Code: 4934 Tokyo Stock Exchange)  
 Representative: Kiyoshi Matsuura  
 President  
 Inquiries: Yuka Uehara  
 Head of Corporate Communication Division and  
 Executive Officer  
 Phone: +81-3-3502-2020

## Notice concerning revision of full year consolidated earnings forecasts

Premier Anti-Aging Co., Ltd. (“the Company”) announces that at the Board of Directors meeting held on June 12, 2026, it has decided to revise the full year consolidated earnings forecasts for the fiscal year ending July 31, 2026 (August 1, 2025 to July 31, 2026) as follows.

1. Revision of consolidated earnings forecasts for the fiscal year ending July 31, 2026 (August 1, 2025 to July 31, 2026)

(Millions of yen)

	Net sales	Operating profit	Ordinary profit	Profit attributable to owners of parent	Basic earnings per share
Previous Forecast (A) (September 11, 2025)	16,500	300	300	300	34.40 yen
Revised Forecast (B)	13,500	300	300	300	34.40 yen
Difference (B – A)	(3,000)	0	0	0	
Rate of Change (%)	(18.2)	0.0	0.0	0.0	
(Reference) Previous Actual Results (Fiscal Year ended July 2025)	16,160	617	599	471	54.10 yen

2. Rational for revision

During the first nine months of the fiscal year ending July 31, 2026, mail order sales in the anti-aging business conducted by the Company fell short of projection as it is taking time for new customer acquisition to recover. In addition, sales of the recovery business conducted through subsidiary Venex Co., Ltd. also fell short of projection due to the impact of intensifying competition, including from e-commerce malls, resulting in an overall sales fell short of projection.

On the profit side, in the recovery business, we actively promoted advertising and promotional investments

related to improving brand recognition and raising awareness of recovery. However, in the anti-aging business, the efficiency of advertising for acquiring new customers did not improve sufficiently, resulting in sales expenses, mainly advertising expenses, falling below projection. In addition, fixed costs such as personnel expenses and outsourcing expenses were reduced more than planned through the promotion of cost structure reforms. As a result, operating profit, ordinary profit, and profit attributable to owners of parent all exceeded our initial projections.

Regarding the full-year sales forecast, while we expect solid sales in our recovery business to continue, mainly through offline channels such as department stores, due to the expansion of the recovery market, we anticipate that sales through online channels, including e-commerce malls, will fall below initial projections due to increased competition. Furthermore, the business environment surrounding the anti-aging business remains challenging. In addition to mail order and wholesale sales, we continue to maintain a cautious stance regarding the Chinese market, and sales in the anti-aging business are also expected to fall below initial projections.

Regarding profits, in addition to the decrease in sales, in the fourth quarter, we plan to continue challenging ourselves with new methods of acquiring new customers in our anti-aging business, as well as investing in advertising and promotion for "DUO Cleanse Serum Peel & Boost," a new line of cleansing serums from the DUO brand and another new products from DUO brand. In addition, for the recovery business, we plan to make aggressive marketing investments to increase awareness of the Venex brand and promote further sales growth. As a result, operating profit is expected to decrease from the 742 million yen recorded for the first nine months of the fiscal year ending July 31, 2026, ending at the level initially projected.

In light of the above circumstances, we have revised our full year consolidated earnings forecasts for the fiscal year ending July 31, 2026 as stated above.

(Note) The above forecast is based on the information currently available, and the actual results may differ due to various factors in the future.